Skip to main content

Advertisement

SpringerLink
Log in

Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates—Toronto Sunnybrook Regional Cancer Centre experience

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

The use of both bisphosphonates and palliative radiotherapy for the prevention and treatment of skeletal complications in women with bone metastases from breast cancer is well established. We undertook an evaluation of palliative radiotherapy utilization rates in breast cancer patients who received bisphosphonates for the treatment of bone metastases in a major Canadian cancer center.

Methods

Charts and electronic files of breast cancer patients with bone metastases who had received either clodronate or pamidronate at any time between January 2000 and December 2001 at our center were retrospectively reviewed. The utilization rates of palliative radiotherapy in these patients were examined.

Results

The percentage of patients receiving bisphosphonates for the treatment of bone metastases who also received palliative radiotherapy to bone remained relatively constant over our study period in the range of 70%. In patients commenced on bisphosphonates before 1998, 42.9% received palliative radiotherapy as initial therapy for bone metastases, whereas in 2001 only 27.8% of patients received palliative radiotherapy before commencing bisphosphonate therapy. There has been a marked improvement in the time between the diagnosis of bone metastases and the commencement of bisphosphonates from a median of 446 days before 1998 to 21 days in 2001. At the same time, there was also an improvement in time between diagnosis of bone metastases and initiation of palliative radiotherapy from a median of 265 days before 1998 to 49 days in 2001.

Conclusion

Use of bisphosphonates has not reduced the utilization rates of palliative radiotherapy in breast cancer patients with bone metastases. There is a trend of initiating bisphosphonates before delivery of palliative radiotherapy. The latter was also delivered earlier in the course of bone metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Berenson JR, Lipton A, Rosen CJ, et al (1998) Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood [Suppl 1] 88:586a

  2. Bessler W, Weber S (1977) Die. Strahlenbehandlung von Knochenmetastasen bei Mammacarcinom. Schweiz Rundsch Med Prax 66:140

    CAS  PubMed  Google Scholar 

  3. Body JJ, Bartl R, Bruckhardt P for the International Bone and Cancer Study Group: Current use of bisphosphonates in oncology (1998) J Clin Oncol 16:3890–3899

    CAS  PubMed  Google Scholar 

  4. Body JJ, Lichinister MR, Diehl IE et al (1999) Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proc Am Soc Clin Oncol 18:575a

    Google Scholar 

  5. Bone Pain Trial Working Party(1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with multi-fraction schedule over 12 months of patient follow-up. Radiother Oncol 52:111–121

    Article  PubMed  Google Scholar 

  6. Breast Cancer Disease Site Group (2000) Use of bisphosphonates in patients with bone metastases from breast cancer. CCO Practice Guideline Initiative. Available at http://www.hiru.mcmaster.ca/ccopgi/guidelines/bre/cpg1_11.html

  7. Coleman R (1997) Skeletal complications of malignancy. Cancer 80:1588–1594

    CAS  PubMed  Google Scholar 

  8. Coleman R, Rubens R (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66

    CAS  PubMed  Google Scholar 

  9. Conte P, Latreille L, Mauriac L, et al (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14:2552–2559

    CAS  PubMed  Google Scholar 

  10. Diel I (1999) Continual PO versus IV interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proc Am Soc Clin Oncol. Abstract 488

  11. Diel I, Solomayer E, Costa S, Gollan C, Goerner R, Wallwiener D, et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357–363

    Google Scholar 

  12. Elomaa I, Blomqvist C, Grohn P, et al (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146–149

    Article  CAS  PubMed  Google Scholar 

  13. Elomaa I, Blomqvist C, Porkka L, et al (1987) Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 8:S53-S56

    PubMed  Google Scholar 

  14. Garmatis GJ, Chu FCH (1978) The effectiveness of radiation therapy in the treatment of bone metastases from breast cancer. Radiology 126:235

    CAS  PubMed  Google Scholar 

  15. Hill M, Richards M, Gregory W, Smith P, Rubens R (1993) Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 68:969–973

    CAS  PubMed  Google Scholar 

  16. Hillner BE, Ingle JN, Berenson JR et al (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378–1391

    CAS  PubMed  Google Scholar 

  17. Hortobagyi G, Theriault R, Porter L, Blayney D, Lipton A, Sinoff C, et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1791

    Google Scholar 

  18. Hortobagyi G, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C, et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038–2044

    CAS  PubMed  Google Scholar 

  19. Hoskin PJ, Price P, Easton D, et al (1992) A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 23:74–78

    CAS  PubMed  Google Scholar 

  20. Koswig S, Budach V (1999) Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study [in German]. Strahlenther Onkol 175:500–508

    Article  CAS  PubMed  Google Scholar 

  21. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–90

    CAS  PubMed  Google Scholar 

  22. Martoni A, Guaraldi M, Camera P, et al (1991) Controlled clinical study on the use of dichloromethylene diphosphate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48:97–101

    CAS  PubMed  Google Scholar 

  23. Mundy G (1997) Mechanisms of bone metastasis. Cancer 80:1546–1556

    CAS  PubMed  Google Scholar 

  24. Paterson A, Powles T, Kanis J, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59–65

    CAS  PubMed  Google Scholar 

  25. Price P, Hoskin P, Easton D, et al (1986) Prospective randomized trial of single and multi-fraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247–255

    CAS  PubMed  Google Scholar 

  26. Rubens R (1998) Bone metastases—the clinical problem. Eur J Cancer 34:210–213

    CAS  PubMed  Google Scholar 

  27. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ, for the Protocol 18 Aredia Breast Cancer Study Group (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol (17)3:846–854

    Google Scholar 

  28. van Holten-Verzantvoort A, Bijvoet O, Cleton F, et al (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2:983–985

    PubMed  Google Scholar 

  29. van Holten-Verzantvoort A, Zwinderman A, Aaronson N, et al (1991) The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544–549

    PubMed  Google Scholar 

  30. van Holten-Verzantvoort A, Kroon H, Bijvoet O, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993; 11:491–498

    Google Scholar 

  31. Wong R, Wiffen J (2002) Bisphosphonates for the relief of pain secondary to bone metastases. In: The Cochrane Library, Oxford

  32. Wu J, Wong R, Johnston M, et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Rad Oncol Biol Phys 55(3): 594–605

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Western Ontario, London, Ontario, Canada

    Katherine Enright

  2. Department of Medical Oncology, Bone Metastases Site Group, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada

    Mark Clemons

  3. Department of Radiation Oncology, Bone Metastases Site Group, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4 N 3M5, Canada

    Edward Chow

Authors
  1. Katherine Enright
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Chow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Enright, K., Clemons, M. & Chow, E. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates—Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer 12, 48–52 (2004). https://doi.org/10.1007/s00520-003-0548-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-003-0548-3

Keywords

Search

Navigation